What is Theravance Biopharma's restricted cash?

Theravance Biopharma (TBPH) reported restricted cash of $836K in Q1 2026.

How has Theravance Biopharma's restricted cash changed year-over-year?

Theravance Biopharma's restricted cash decreased by 0.0% year-over-year, from $836K to $836K.

What is the long-term trend for Theravance Biopharma's restricted cash?

Over 5 years (2020 to 2025), Theravance Biopharma's restricted cash has grown at a 0.1% compound annual growth rate (CAGR), from $833K to $836K.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Theravance Biopharma TBPH Restricted Cash

Restricted Cash at other companies

LQD

Liquidia CorporationLQDA

$3.5M—

Aurinia PharmaceuticalsAUPH

$259K-17.8%

Mirum Pharmaceuticals, Inc.MIRM

$1.73M+308%

ALN

Alnylam PharmaceuticalsALNY

$1.64M-36.8%

BridgeBio PharmaBBIO

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+68.7%

Enterprise value$642.72M+38.3%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's restricted cash?: Theravance Biopharma (TBPH) reported restricted cash of $836K in Q1 2026.
How has Theravance Biopharma's restricted cash changed year-over-year?: Theravance Biopharma's restricted cash decreased by 0.0% year-over-year, from $836K to $836K.
What is the long-term trend for Theravance Biopharma's restricted cash?: Over 5 years (2020 to 2025), Theravance Biopharma's restricted cash has grown at a 0.1% compound annual growth rate (CAGR), from $833K to $836K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.